SCHEMBL209203

SCHEMBL209203

COC(=O)C(=O)Nc1ccc(F)cc1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.69
ALDH1A1 P00352 3/20 0.58
RAB9A P51151 5/20 0.56
MEN1 O00255 5/20 0.56
KMT2A Q03164 5/20 0.56
NPC1 O15118 4/20 0.56
MAPK1 P28482 3/20 0.56
HTT P42858 2/20 0.56
ATM Q13315 1/20 0.54
POLB P06746 1/20 0.50
KDM4E B2RXH2 2/20 0.49
XBP1 P17861 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
MAOA P21397 1/20 0.49
MAOB P27338 1/20 0.49
TGM2 P21980 1/20 0.48
CYP2C19 P33261 1/20 0.47
GAA P10253 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
TAAR1 Q96RJ0 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3276446 0.84 ALDH1A1 (0.58) MAPTALDH1A1RAB9AMEN1KMT2A
SCHEMBL3276441 0.84 ALDH1A1 (0.58) MAPTALDH1A1RAB9AMEN1KMT2A
SCHEMBL21568085 0.83 ALDH1A1 (0.67) MAPTALDH1A1RAB9AMEN1KMT2A
SCHEMBL11061083 0.82 MAPT (1.00) MAPTALDH1A1MEN1KMT2AHTT
SCHEMBL3307191 0.82 NPC1 (0.60) MAPTALDH1A1RAB9AKMT2ANPC1
SCHEMBL626576 0.82 MAPT (0.57) MAPTALDH1A1RAB9AMEN1KMT2A
SCHEMBL29764757 0.81 MAPT (0.53) MAPTALDH1A1RAB9AMEN1KMT2A
SCHEMBL1503836 0.81 TSHR (0.55) MAPTALDH1A1RAB9AMEN1KMT2A
SCHEMBL5548239 0.80 RAB9A (0.56) MAPTALDH1A1RAB9AMEN1KMT2A
SCHEMBL18415556 0.80 RAB9A (0.68) MAPTALDH1A1RAB9AMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200352931-A1 OXALAMIDES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE Phenex Discovery Verwaltungs-GmbH (DE) 2020-11-12 US disclosed
WO-2019115586-A1 OXALAMIDES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE Phenex Discovery Verwaltungs-GmbH (DE) 2019-06-20 WO disclosed
EP-1405852-B9 DIAMINE DERIVATIVES DAIICHI SANKYO CO LTD (JP) 2013-03-27 EP disclosed
CN-1826333-B Diamine derivatives DAIICHI SANKYO CO LTD 2012-12-26 CN disclosed
EP-1577301-B1 Antithrombotic diaminocyclohexane derivatives DAIICHI SANKYO CO LTD (JP) 2012-09-12 EP disclosed
EP-1405852-B1 DIAMINE DERIVATIVES DAIICHI SANKYO CO LTD (JP) 2012-08-01 EP disclosed
US-8088796-B2 Triamine derivative DAIICHI SANKYO COMPANY, LIMITED (JP) 2012-01-03 US disclosed
US-20110312990-A1 Diamine Derivatives DAIICHI SANKYO COMPANY, LIMITED (JP) 2011-12-22 US disclosed
US-20110312990-A1 Diamine Derivatives DAIICHI SANKYO COMPANY, LIMITED (JP) 2011-12-22 US disclosed
US-20110312990-A1 Diamine Derivatives DAIICHI SANKYO COMPANY, LIMITED (JP) 2011-12-22 US disclosed
CN-1751025-A Diamine derivatives DAIICHI SEIYAKU CO (JP) 2006-03-22 CN disclosed
CN-1745071-A Novel ethylenediamine derivative DAIICHI SEIYAKU CO (JP) 2006-03-08 CN disclosed
US-20050245565-A1 Diamine derivatives DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2005-11-03 US disclosed
EP-1577301-A1 DIAMINE DERIVATIVES DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2005-09-21 EP disclosed
EP-1577302-A1 NOVEL ETHYLENEDIAMINE DERIVATIVES DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2005-09-21 EP disclosed
US-20050119486-A1 Diamine derivatives DAIICHI SANKYO COMPANY, LIMITED (JP) 2005-06-02 US disclosed
US-20050020645-A1 Diamine derivatives DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2005-01-27 US disclosed
EP-1415992-A1 DIAMINE DERIVATIVES DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2004-05-06 EP disclosed
EP-1405852-A1 DIAMINE DERIVATIVES DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2004-04-07 EP disclosed
US-4483707-A PLANT SAFTENING AGENTS CIBA-GEIGY CORPORATION (US) 1984-11-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200352931-A1 OXALAMIDES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE IDO1, IDO2, INMT MAPT 2184/4885ALDH1A1 825/4885RAB9A 4766/4885
US-20050020645-A1 Diamine derivatives C9, C1S, C1R MAPT 4271/4885ALDH1A1 3319/4885RAB9A 3294/4885
US-20050245565-A1 Diamine derivatives C9, C1S, C1R MAPT 4271/4885ALDH1A1 3319/4885RAB9A 3294/4885
US-20050119486-A1 Diamine derivatives C9, C1S, C1R MAPT 4271/4885ALDH1A1 3319/4885RAB9A 3294/4885
US-20110312990-A1 Diamine Derivatives C9, C1S, C1R MAPT 4230/4885ALDH1A1 3734/4885RAB9A 3496/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.